Bahija Jallal, Immunocore CEO
FDA hurries up a quick approval for the world's first TCR — after a 14-year R&D trek
Over the 14 years since Immunocore was spun out of MediGene in a quest to develop a gamechanging cancer med, the biotech has raised record …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
